Merck Successfully Divests Allergopharma

Merck Successfully Divests Allergopharma

Darmstadt, Germany, March 31, 2020 – Merck, a leading science and technology company, today completed the divestment of Allergopharma to Dermapharm Holding SE (“Dermapharm”) following regulatory approval and the satisfaction of other customary closing conditions. With the successful transaction closing, the Healthcare business sector will further sharpen its focus on the development of innovative medicines for difficult-to-treat diseases. The allergy business of Merck in Europe was transferred to Dermapharm on March 31. The transfer of the Allergopharma business in China is planned for the second half of 2020. The two parties have agreed not to disclose the purchase price.